Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Pharma Companies Ask for More Clarity in ICH E9 Addendum

  • Post author:Sam
  • Post published:April 26, 2018
  • Post category:Drug Industry Daily

In comments to the European Medicines Agency, leading drugmakers requested more clarification, simpler language and various other revisions for the International Conference on Harmonisation’s draft addendum to its E9 guidelines.…

Continue ReadingPharma Companies Ask for More Clarity in ICH E9 Addendum

FDA Issues Final Guidance on Imaging-Based Clinical Trial Endpoints

  • Post author:Sam
  • Post published:April 26, 2018
  • Post category:Drug Industry Daily

Sponsors conducting clinical trials using imaging-based primary endpoints should consider the choice of modality — such as echocardiography or single-photon emission computed tomography — as well as centralized image interpretation…

Continue ReadingFDA Issues Final Guidance on Imaging-Based Clinical Trial Endpoints

UK Plans to Stick With EU Clinical Trial Regulations Post-Brexit

  • Post author:Sam
  • Post published:April 25, 2018
  • Post category:Drug Industry Daily

The UK government aims to stay up-to-date with EU changes for clinical trial procedures amid uncertainties over next March’s implementation of Brexit. Source: Drug Industry Daily

Continue ReadingUK Plans to Stick With EU Clinical Trial Regulations Post-Brexit

Joint Advisory Committee Votes Celebrex Trial Demonstrated Safety

  • Post author:Sam
  • Post published:April 25, 2018
  • Post category:Drug Industry Daily

The FDA’s Arthritis and Drug Safety Committee and the Risk Management Advisory Committee voted 15 to 5, with a single abstention, that Pfizer’s PRECISION trial, which compared Celebrex (celecoxib) to…

Continue ReadingJoint Advisory Committee Votes Celebrex Trial Demonstrated Safety

FDA Extends Electronic Submission Deadline for Type III Drug Master Files

  • Post author:Sam
  • Post published:April 25, 2018
  • Post category:Drug Industry Daily

The FDA issued final guidance on electronic submissions of drug master files, giving sponsors of Type III DMFs for packaging materials an extra year before submission requirements kick in. Source:…

Continue ReadingFDA Extends Electronic Submission Deadline for Type III Drug Master Files

Supreme Court Rules Inter Partes Review Procedure Constitutional

  • Post author:Sam
  • Post published:April 25, 2018
  • Post category:Drug Industry Daily

In a landmark decision for patent law, and to the disappointment of some drug makers, the U.S. Supreme Court upheld the legality of inter partes reviews, preserving a method that…

Continue ReadingSupreme Court Rules Inter Partes Review Procedure Constitutional

Teamsters Sue Drugmakers, Distributors, PBMs Over Opioids

  • Post author:Sam
  • Post published:April 24, 2018
  • Post category:Drug Industry Daily

Adding to the already numerous lawsuits, the Teamsters union sued opioid manufacturers, distributors and pharmacy benefit managers in the U.S. District Court for the Northern District of Ohio over their…

Continue ReadingTeamsters Sue Drugmakers, Distributors, PBMs Over Opioids

CDER Updates Policies on Expedited Review of Prior Approval Supplements

  • Post author:Sam
  • Post published:April 24, 2018
  • Post category:Drug Industry Daily

CDER released a revised Manual of Policies and Procedures on expedited reviews of prior approval supplements for new drug and biologics license applications that involve chemistry, manufacturing and controls changes.…

Continue ReadingCDER Updates Policies on Expedited Review of Prior Approval Supplements

Senate HELP Committee Advances Opioid Crisis Bill Without Tougher Drugmaker Penalties

  • Post author:Sam
  • Post published:April 24, 2018
  • Post category:Drug Industry Daily

The Senate Committee on Health, Education, Labor and Pensions unanimously advanced the Opioid Crisis Response Act (S. 2680) Tuesday but voted down an amendment to impose tough penalties on drugmakers.…

Continue ReadingSenate HELP Committee Advances Opioid Crisis Bill Without Tougher Drugmaker Penalties

Gottlieb Flags FDA’s Plans for Generics in Senate Appropriations Hearing

  • Post author:Sam
  • Post published:April 24, 2018
  • Post category:Drug Industry Daily

Generic drug approvals were in the spotlight during remarks by FDA Commissioner Scott Gottlieb before a Senate appropriations subcommittee on the FDA’s fiscal year 2019 budget request. Source: Drug Industry…

Continue ReadingGottlieb Flags FDA’s Plans for Generics in Senate Appropriations Hearing
  • Go to the previous page
  • 1
  • …
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.